ClinicalTrials.gg
RecruitingNCT07338955Updated Jan 14, 2026

Validating and Assessing Reliability

An observational study in Upper Limb Disability, sponsored by Bahria University. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Bahria University · Observational

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
385
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study aims to translate, culturally adapt, and validate the Urdu version of the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire for individuals with upper limb disabilities. Since no validated Urdu version currently exists, Urdu-speaking patients face communication barriers that may lead to inaccurate assessment and limited clinical decision-making. By ensuring semantic equivalence through forward-backward translation and expert review, the study seeks to develop a version that is both linguistically accurate and culturally appropriate.

Read the detailed description

This study aims to translate, culturally adapt, and validate the Urdu version of the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire for individuals with upper limb disabilities. Since no validated Urdu version currently exists, Urdu-speaking patients face communication barriers that may lead to inaccurate assessment and limited clinical decision-making. By ensuring semantic equivalence through forward-backward translation and expert review, the study seeks to develop a version that is both linguistically accurate and culturally appropriate.

A cross-sectional research design will be used, involving adults aged 18-45 years diagnosed with upper limb functional limitations. Participants will complete both the Urdu and English DASH questionnaires to evaluate reliability and validity. Reliability will be assessed through internal consistency (Cronbach's alpha) and test-retest stability (ICC), while validity will be examined using expert scoring (CVI) and correlation with the original instrument. Data analysis will follow standard psychometric testing procedures using SPSS.

The expected outcome is a reliable, valid tool for assessing upper extremity disability in Urdu-speaking populations. This will improve clinical assessment, enhance patient communication, and support broader inclusion in rehabilitation research and practice.

02

Conditions studied

  • Upper Limb Disability

Keywords

  • Validation and Reliability of DASH Questionnaire
03

In context

Lead sponsor

Bahria University is the lead sponsor of 36 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with upper limb disability or pain for more than 4 weeks

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosed with any upper limb disability or deformity . Able to read, understand and speak Urdu. Individuals with symptoms enduring for at least one week .

Exclusion criteria

Exclusion Criteria:

Cognitive impairment or psychiatric illness that hinders understanding of the questionnaire.

Patients with congenital deformities. Refusal to give .

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
385 participants (estimated)
Target follow-up
385 Weeks
Patient registry
Yes

Groups and cohorts

  • Group 1

    Data will be collected from experienced physiotherpist

    Other: All participants (Aviane) · Other: data collection

Interventions

  • OtherAll participants (Aviane)

    Data will be collected from patients having upper limb pain or disability

  • Otherdata collection

    Data will be collected from patients having upper limb pain or disbility

06

What researchers measure

Primary outcomes

  1. reliability and validity

    To assess the reliability and validity of the Urdu version of the DASH Questionnaire.

    Time frame: December 2025 to January 2026

Secondary outcomes

  1. cultural adaptation

    To ensure the cultural adaptation, response of the patient and to compare the results of DASH Questionnaire Urdu version with English version of DASH Questionnaire.

    Time frame: October 2025 to November2025

07

Study locations

1 of 1 sites recruiting
  • University
    Karachi, Sindh 75300, Pakistan
    Recruiting
    • Muhammad Usman, Masters in Physiotherpy · Contactusman.bumdc@gmail.com · +923333172771
    • Rabia Khan, Masters in Physiotherapy · Principal investigator
08

References and documents

Publications

  • Basakci Calik B, Demir P, Gur Kabul E, Caglayan BC, Keskin A, Karasu U. Validity and Reliability of the Turkish Version of the DASH-TR Questionnaire in Rheumatoid Arthritis Patients, Based on Rasch Analysis. Int J Rheum Dis. 2022 Aug;25(8):851-860. doi: 10.1111/1756-185X.14358. Epub 2022 Jun 6. PubMed 35665605 ↗
  • Puentes Gutierrez AB, Garcia Bascones M, Jimenez Diaz F, Cuena Boy R, Puentes Gutierrez R. [Validity and reliability of DASH questionnaire in women who suffer from lymphedema as a side effect of a breast cancer treatment]. Rehabilitacion (Madr). 2023 Jul-Sep;57(3):100780. doi: 10.1016/j.rh.2022.100780. Epub 2023 Feb 3. Spanish. PubMed 36739630 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Dec 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Jan 14, 2026
StartActual
Nov 3, 2025
Primary completionActual
Dec 10, 2025
CompletionEst.
Jan 20, 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07338955
Lead sponsor
Bahria University
Responsible party
Rabia Khan (Assistant Professor, Bahria University) — Principal investigator
First posted
Jan 14, 2026
Start date
Nov 3, 2025
Primary completion
Dec 10, 2025
Completion
Jan 20, 2026 (estimated)
Last update
Jan 14, 2026

Study contacts

Rabia Khan, Masters in Physiotherapy
Contact
iamrabiakhan@gmail.com
+923452310047

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion